Roth Capital Reinstates Buy on Monopar Therapeutics, Announces $18 Price Target

Roth Capital analyst Kumaraguru Raja reinstates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and announces $18 price target.

byBenzinga Newsdesk

December 9, 2022

1 minute read

Roth Capital analyst Kumaraguru Raja reinstates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and announces $18 price target.

Century Aluminum Issues Statement Of Support For New Biden Administration Tariffs On Russian Aluminum

By Happy Mohamed

Today, 2:22 AM

Century Aluminum Company (NASDAQ:CENX) today released the following statement from President and Chief Executive Officer Jesse Gary in support of the Biden administration's decision to implement

CENX

Masonite Analyst Re-Rates Stock After Non-Recurring Restructuring Charges For Cost Savings

By Anusuya Lahiri

Today, 2:22 AM

Wedbush reiterated Outperform on Masonite International Corp (NYSE: DOOR) with a $115.00 price target.

DOOR

Capri Holdings To Be Swayed By Macro Uncertainty & FX Pressure, Says Analyst

By Shivani Kumaresan

Today, 2:22 AM

Telsey Advisory Group analyst Dana Telsey reiterated a Market Perform rating on the shares of Capri Holdings Ltd (NYSE:CPRI) and lowered…

CPRI

InMed Reports FY22 Net Loss Of $33.17/Share Compared To A Net Loss Of $37.96/Share YoY

By Benzinga Newsdesk

Today, 2:22 AM

For the year ended June 30, 2022, the Company recorded a net loss of $18.6 million, or $33.17 per share, compared with a net loss of $10.2 million or $37.96 per share, for the previous

INM

Roth Capital Reinstates Buy on Monopar Therapeutics, Announces $18 Price Target

Related Posts

Century Aluminum Issues Statement Of Support For New Biden Administration Tariffs On Russian Aluminum

Masonite Analyst Re-Rates Stock After Non-Recurring Restructuring Charges For Cost Savings

Capri Holdings To Be Swayed By Macro Uncertainty & FX Pressure, Says Analyst

InMed Reports FY22 Net Loss Of $33.17/Share Compared To A Net Loss Of $37.96/Share YoY